113 related articles for article (PubMed ID: 30715891)
1. Biodegradable Hyaluronic Acid Modified with Tetraglycine-l-octaarginine as a Safe Adjuvant for Mucosal Vaccination.
Ukawa M; Tanishita S; Yagi H; Yoshida Y; Tomono T; Shigeno K; Tobita E; Uto T; Baba M; Sakuma S
Mol Pharm; 2019 Mar; 16(3):1105-1118. PubMed ID: 30715891
[TBL] [Abstract][Full Text] [Related]
2. Nasal absorption enhancement of protein drugs independent to their chemical properties in the presence of hyaluronic acid modified with tetraglycine-L-octaarginine.
Tomono T; Yagi H; Ukawa M; Ishizaki S; Miwa T; Nonomura M; Igi R; Kumagai H; Miyata K; Tobita E; Kobayashi H; Sakuma S
Eur J Pharm Biopharm; 2020 Sep; 154():186-194. PubMed ID: 32681963
[TBL] [Abstract][Full Text] [Related]
3. Cross-Protective Abilities of Hyaluronic Acid Modified with Tetraglycine-l-octaarginine as a Mucosal Adjuvant against Infection with Heterologous Influenza Viruses.
Tanishita S; Ukawa M; Tomono T; Yoshida Y; Tsujioka T; Miyata K; Tobita E; Uto T; Baba M; Sakuma S
Bioconjug Chem; 2019 Dec; 30(12):3028-3037. PubMed ID: 31738536
[TBL] [Abstract][Full Text] [Related]
4. Cross-reactivity of immunoglobulin A secreted on the nasal mucosa in mice nasally inoculated with inactivated H1N1 influenza A viruses in the presence of D-octaarginine-linked polymers.
Sakuma S; Morimoto N; Nishida K; Murakami T; Egawa T; Endo R; Kataoka M; Yamashita S; Miyata K; Mohri K; Ochiai K; Hiwatari K; Koike S; Tobita E; Uto T; Baba M
Eur J Pharm Biopharm; 2015 May; 92():56-64. PubMed ID: 25720816
[TBL] [Abstract][Full Text] [Related]
5. Effects of the Chemical Structures of Oligoarginines Conjugated to Biocompatible Polymers as a Mucosal Adjuvant on Antibody Induction in Nasal Cavities.
Mohri K; Miyata K; Egawa T; Tanishita S; Endo R; Yagi H; Ukawa M; Ochiai K; Hiwatari KI; Tsubaki K; Shigeno K; Tobita E; Uto T; Baba M; Sakuma S
Chem Pharm Bull (Tokyo); 2018; 66(4):375-381. PubMed ID: 29607903
[TBL] [Abstract][Full Text] [Related]
6. Cell-penetrating peptide-linked polymers as carriers for mucosal vaccine delivery.
Sakuma S; Suita M; Inoue S; Marui Y; Nishida K; Masaoka Y; Kataoka M; Yamashita S; Nakajima N; Shinkai N; Yamauchi H; Hiwatari K; Tachikawa H; Kimura R; Uto T; Baba M
Mol Pharm; 2012 Oct; 9(10):2933-41. PubMed ID: 22953762
[TBL] [Abstract][Full Text] [Related]
7. Demonstration of d-Octaarginine-Linked Polymers as Promising Adjuvants for Mucosal Vaccination through Influenza Virus Challenge.
Miyata K; Mohri K; Egawa T; Endo R; Morimoto N; Ochiai K; Hiwatari K; Tsubaki K; Tobita E; Uto T; Baba M; Sakuma S
Bioconjug Chem; 2016 Aug; 27(8):1865-71. PubMed ID: 27463562
[TBL] [Abstract][Full Text] [Related]
8. Performance of Cell-Penetrating Peptides Anchored to Polysaccharide Platforms Applied via Various Mucosal Routes as an Absorption Enhancer.
Yagi H; Tomono T; Handa Y; Saito N; Ukawa M; Miyata K; Shigeno K; Sakuma S
Mol Pharm; 2023 Jan; 20(1):303-313. PubMed ID: 36484773
[TBL] [Abstract][Full Text] [Related]
9. Mechanism on antigen delivery under mucosal vaccination using cell-penetrating peptides immobilized at multiple points on polymeric platforms.
Ukawa M; Endo R; Yagi H; Tomono T; Miyata K; Shigeno K; Tobita E; Uto T; Baba M; Sakuma S
Int J Pharm; 2022 Feb; 613():121376. PubMed ID: 34915143
[TBL] [Abstract][Full Text] [Related]
10. Oligoarginine-linked polymers as a new class of penetration enhancers.
Sakuma S; Suita M; Masaoka Y; Kataoka M; Nakajima N; Shinkai N; Yamauchi H; Hiwatari K; Tachikawa H; Kimura R; Yamashita S
J Control Release; 2010 Dec; 148(2):187-96. PubMed ID: 20800631
[TBL] [Abstract][Full Text] [Related]
11. Mucosal absorption of antibody drugs enhanced by cell-penetrating peptides anchored to a platform of polysaccharides.
Tomono T; Yagi H; Igi R; Tabaru A; Fujimoto K; Enomoto K; Ukawa M; Miyata K; Shigeno K; Sakuma S
Int J Pharm; 2023 Nov; 647():123499. PubMed ID: 37832700
[TBL] [Abstract][Full Text] [Related]
12. Consecutive inoculations of influenza virus vaccine and poly(I:C) protects mice against homologous and heterologous virus challenge.
Moriyama M; Chino S; Ichinohe T
Vaccine; 2017 Feb; 35(7):1001-1007. PubMed ID: 28111142
[TBL] [Abstract][Full Text] [Related]
13. Acquisition of absorption-enhancing abilities of cationic oligopeptides with short chain arginine residues through conjugation to hyaluronic acid.
Tomono T; Yagi H; Kanemoto S; Ukawa M; Miyata K; Shigeno K; Sakuma S
Int J Pharm; 2022 Mar; 616():121519. PubMed ID: 35093459
[TBL] [Abstract][Full Text] [Related]
14. Cell-Penetrating Peptide Penetratin as a Potential Tool for Developing Effective Nasal Vaccination Systems.
Muto K; Kamei N; Yoshida M; Takayama K; Takeda-Morishita M
J Pharm Sci; 2016 Jun; 105(6):2014-2017. PubMed ID: 27155764
[TBL] [Abstract][Full Text] [Related]
15. Biocompatible Polymers Modified with d-Octaarginine as an Absorption Enhancer for Nasal Peptide Delivery.
Miyata K; Ukawa M; Mohri K; Fujii K; Yamada M; Tanishita S; Higashitarumi S; Ishizaki S; Kumagai H; Ochiai K; Hiwatari KI; Tsubaki K; Shigeno K; Tobita E; Kobayashi H; Sakuma S
Bioconjug Chem; 2018 May; 29(5):1748-1755. PubMed ID: 29648441
[TBL] [Abstract][Full Text] [Related]
16. Mucosal and systemic antibody responses against an acellular pertussis vaccine in mice after intranasal co-administration with recombinant cholera toxin B subunit as an adjuvant.
Isaka M; Yasuda Y; Taniguchi T; Kozuka S; Matano K; Maeyama J; Morokuma K; Ohkuma K; Goto N; Tochikubo K
Vaccine; 2003 Mar; 21(11-12):1165-73. PubMed ID: 12559794
[TBL] [Abstract][Full Text] [Related]
17. Intranasal vaccination of recombinant H5N1 HA1 proteins fused with foldon and Fc induces strong mucosal immune responses with neutralizing activity: Implication for developing novel mucosal influenza vaccines.
Yu F; Li Y; Guo Y; Wang L; Yang J; Zhao G; Zhou Y; Du L; Jiang S
Hum Vaccin Immunother; 2015; 11(12):2831-8. PubMed ID: 26260706
[TBL] [Abstract][Full Text] [Related]
18. Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection.
Hong SH; Byun YH; Nguyen CT; Kim SY; Seong BL; Park S; Woo GJ; Yoon Y; Koh JT; Fujihashi K; Rhee JH; Lee SE
Vaccine; 2012 Jan; 30(2):466-74. PubMed ID: 22051136
[TBL] [Abstract][Full Text] [Related]
19. Intranasal Immunization Using Mannatide as a Novel Adjuvant for an Inactivated Influenza Vaccine and Its Adjuvant Effect Compared with MF59.
Ren ST; Zhang XM; Sun PF; Sun LJ; Guo X; Tian T; Zhang J; Guo QY; Li X; Guo LJ; Che J; Wang B; Zhang H
PLoS One; 2017; 12(1):e0169501. PubMed ID: 28052136
[TBL] [Abstract][Full Text] [Related]
20. Nasal aluminum (oxy)hydroxide enables adsorbed antigens to induce specific systemic and mucosal immune responses.
Xu H; Ruwona TB; Thakkar SG; Chen Y; Zeng M; Cui Z
Hum Vaccin Immunother; 2017 Nov; 13(11):2688-2694. PubMed ID: 28933668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
